0001209191-20-053872.txt : 20201005
0001209191-20-053872.hdr.sgml : 20201005
20201005184631
ACCESSION NUMBER: 0001209191-20-053872
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201001
FILED AS OF DATE: 20201005
DATE AS OF CHANGE: 20201005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sukhtian Faisal Ghiath
CENTRAL INDEX KEY: 0001716033
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 201224987
MAIL ADDRESS:
STREET 1: 7TH CIRCLE, ZAHRAN ST.
STREET 2: ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909
CITY: AMMAN
STATE: M2
ZIP: 11844
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 4260 U.S. ROUTE 1
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 4260 U.S. ROUTE 1
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-01
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001716033
Sukhtian Faisal Ghiath
C/O OUTLOOK THERAPEUTICS, INC.
4260 US ROUTE 1
MONMOUTH JUNCTION
NJ
08852
1
0
0
0
Stock Option (Right to Buy)
0.71
2020-10-01
4
A
0
296352
0.00
A
2030-10-01
Common Stock
296352
296352
D
Stock Option (Right to Buy)
0.7052
2020-10-05
4
A
0
151721
0.5141
A
2030-10-05
Common Stock
151721
151721
D
The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.
The options were granted under the 2015 Plan in lieu of $78,000 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.
/s/ Lawrence Kenyon, Attorney-in-Fact
2020-10-05